Related Experiment Videos
[Humanized respiratory syncytial virus monoclonal antibody]
1Department of Pediatrics, Sapporo Medical University School of Medicine.
Insights
Respiratory syncytial virus (RSV) causes severe respiratory illness in children, especially premature infants. Palivizumab, a monoclonal antibody, offers a safe and effective preventative therapy for high-risk infants.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Respiratory Medicine
Context:
- Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants and young children.
- High-risk populations, including premature infants and those with chronic lung or congenital heart disease, face the greatest threat from RSV.
- Current treatment options are limited, primarily relying on supportive care and respiratory support.
Purpose:
- To evaluate the safety and efficacy of palivizumab, a humanized anti-RSV monoclonal antibody, for preventing serious RSV illness.
- To assess the role of prophylactic palivizumab in high-risk pediatric populations.
Summary:
- Palivizumab is administered monthly via intramuscular injection.
- Clinical studies in the USA and Europe have demonstrated that palivizumab prophylaxis is both safe and effective.
- It significantly reduces the incidence of serious RSV illness in premature infants and those with bronchopulmonary dysplasia.
Impact:
- Palivizumab provides a crucial preventative strategy against severe RSV disease in vulnerable children.
- This monoclonal antibody therapy represents a significant advancement in managing RSV in high-risk pediatric populations.
- It offers improved clinical outcomes and reduces the burden of severe respiratory illness in infants.
Abstract:
Respiratory syncytial virus remains a significant cause of severe lower respiratory tract disease in children. The risk of serious RSV illness is highest among children with prematurity, chronic lung disease and congenital heart disease. No effective vaccine and anti-viral agents have been obtained even now. Therefore, conservative therapy including respiratory aid has been a principal therapy for serious RSV disease. Recently, monthly intramuscular administration of humanized anti-RSV monoclonal antibody(palivizumab) was introduced in clinical fields in USA and Europe. Palivizumab prophylaxis has appeared to be safe and effective for prevention of serious RSV illness in premature children and those with bronchopulmonary dysplasia.